Program
Rabies vaccine
Also written as “rabies vaccine” and “Rabies Vaccine”.
Its studies are mostly in Rabies · Malaria · COVID-19 · Meningitis, Meningococcal, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 30 open or running | phase 3since Jun 27, 2006 | Jun 27, 2006 | none ahead |
| Institut Pasteur | 10 open or running | no phasesince Mar 31, 2021 | Mar 31, 2021 | none ahead |
| Sinovac Biotech | 11 open or running | phase 3since May 27, 2025 | May 27, 2025 | Jan 30, 2027phase 3 · NCT07055893 |
Also a collaborator on its studies: Beijing Institute of Biological Products and Changchun Institute of Biological Products.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 27, 2006First study: phase 3 study in RabiesNew to NovartisNovartis · NCT00345319 · 630 enrolled · China
- Nov 3, 2011Phase 3 study in Meningococcal InfectionsNovartis · NCT01466387 · 552 enrolled · Czech Republic, Germany
- Jun 24, 2014Phase 3 study in Rabies InfectionNovartis · NCT02177032 · 885 enrolled · Philippines, Thailand
- Mar 31, 2021Institut Pasteur's first study: no phase study in RabiesNew to Institut PasteurInstitut Pasteur · NCT04829630 · 180 enrolled · Cambodia, Madagascar
- May 27, 2025Sinovac Biotech's first study: phase 3 study in RabiesNew to Sinovac BiotechSinovac Biotech · NCT07055893 · 390 planned · Pakistan
Ahead
- Jan 30, 2027Primary completion: phase 3 study in RabiesSinovac Biotech · NCT07055893
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Rabies vaccine”name, by rule
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07055893Rabies · Pakistan | 3 | Not yet recruiting | Sinovac Biotech | Jan 30, 2027 | 390 |
| NCT04829630Rabies · Cambodia, Madagascar | – | Completed | Institut Pasteur | Feb 1, 2023 | 180 |
| NCT02177032Rabies Infection · Philippines, Thailand | 3 | Completed | Novartis | Oct 2014 | 885 |
| NCT01466387Meningococcal Infections · Czech Republic, Germany | 3 | Completed | Novartis | Apr 2012 | 552 |
| NCT00345319Rabies · China | 3 | Completed | Novartis | May 2006 | 630 |
How it is read
Names in the registry
- “Rabies vaccine”, 4 entries
- “rabies vaccine”, 3 entries
- “Rabies Vaccine”, 2 entries
Conditions, from the studies’ own filings
- Rabies, 5 studies
- Malaria, 1 study
- COVID-19, 1 study
- Meningitis, Meningococcal, 1 study
First seen by our ledger Nov 14, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.